CBS 2019
CBSMD教育中心
首页
CBS 2019
关于CBS
会议通知
会议组织
主办单位
南京市心血管病医院
亚洲分叉病变俱乐部
南京医科大学附属南京医院
南京市第一医院医学发展医疗救助基金会
协办单位
中华医学会心血管病学分会
国家卫生健康委能力建设和继续教育心血管病学专家委员会（CBCEC）
美国心血管造影和介入学会
亚洲心脏学会
北京合众关爱心脏健康基金会
联系我们
境内代表注册管理:
彭红娟 ：
+86-13913895477
徐海梅 ：+86-13914736846
cbsnj@cbsmd.cn
境外代表注册管理:
林玲 ： +86 (25) 52271398
+86-13951884596
cbs@cbsmd.cn
病例征集管理:
赵莹莹 ：+86-13815408517
sub@cbsmd.cn
地址：
江苏省南京市秦淮区长乐路68号，南京市心血管病医院9号楼905区心内科办公室
210006
主席团
主席团
大会主席
联合主席
教育中心
教育中心
• 线上教育 （ 注册后可使用个人定义界面搜集科研图书馆文献、下载教育资源、参与在线病例讨论。）
• 教育资源
• 科研动态
科研图书馆
科研图书馆
科研文章
> 急性冠脉综合征
> 动脉粥样硬化性心血管疾病
> 分叉支架
> 心脏肿瘤科
> 充血性心力衰竭
> 双重抗血小板治疗持续时间
> 药物涂层球囊
> 血流储备分数
> 血管内超声指导
> 光学相关断层扫描
> 肺动脉高压
> 旋磨术
> 血流动力学与动脉粥样硬化
> 左主干支架
> 经导管主动脉瓣置换
> 经皮左心耳封堵
> 二尖瓣/三尖瓣瓣膜
> 推荐文献
荐读文献
Management of Acute Myocardial Infarction During the COVID-19 Pandemic
CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic
ACC临床简报:新型冠状病毒对心脏的影响(2019-nCoV)
SCAI Expert Consensus Statement Update on Best Practices for Transradial Angiography and Intervention
Guideline | By J Brugada, DG Katritsis, ESC Scientific Document Group et al.
Complete Revascularization with Multivessel PCI for Myocardial Infarction
Clinical Trial | By Mehta SR, Wood DA, COMPLETE Trial Steering Committee and Investigators.
BACKGROUND - In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion reduces the risk of cardiovascular death or myocardial infarction. Whether PCI of nonculprit lesions further reduces the risk of such events is unclear. METHODS - We randomly assigned patients with STEMI and multivessel coronary artery disease who ha...
Clinical Trial | By GN Janssens, NW van der Hoeven, JS Lemkes et al.
OBJECTIVES- The aim of the present study was to determine the effect of a delayed versus an immediate invasive approach on final infarct size and clinical outcome up to 1 year. BACKGROUND- Up to 24% of patients with acute coronary syndromes present with ST-segment elevation myocardial infarction (STEMI) but show complete resolution of ST-segment elevation and symptoms before revascularization. Cu...
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Clinical Trial | By DMF Claassens, GJA Vos, TO Bergmeijer et al.
BACKGROUND - It is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors. METHODS - We conducted a randomized, open-label, assessor-blinded trial in which patients undergoing primary PCI with stent implantation were assigned in a 1:1 ratio to receive either a P2Y12 inhibitor on the basis of early CYP2...
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
Clinical Trial | By Schüpke S, Neumann FJ, ISAR-REACT 5 Trial Investigators.
BACKGROUND - The relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain. METHODS - In this multicenter, randomized, open-label trial, we randomly assigned patients who presented with acute coronary syndromes and for whom invasive evaluation was planned to receive either ticagrelor or prasugrel. The primary end point...
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Consensus | By Glikson M, Wolff R, Hindricks G et al.
Chapter 1. Background and pathophysiology of thrombus formation in the left atrium The rationale for the quest to close the left atrial appendage (LAA) for stroke prevention is composed of three elements: the concept that atrial fibrillation (AF) causes strokes, the concept that strokes are associated with thrombus formation in the LAA, and that these thrombi cause strokes by embolisation to the cerebral circulation. There are strong d...
Clinical Trial | By P Vranckx, M Valgimigli, A Goette et al.
BACKGROUND - We aimed to assess the safety of edoxaban in combination with P2Y12 inhibition in patients with atrial fibrillation who had percutaneous coronary intervention (PCI). METHODS - ENTRUST-AF PCI was a randomised, multicentre, open-label, non-inferiority phase 3b trial with masked outcome evaluation, done at 186 sites in 18 countries. Patients had atrial fibrillation requiring oral anticoa...
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Clinical Trial | By SD Solomon, the PARAGON-HF Investigators and Committees. JohnJV McMurray,
BACKGROUND - The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor–neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. METHODS - We randomly assigned 482...
English
CBS 2019
CBS 2019 主席团
教育中心
科研动态
